Exploring QSARs of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitors by MLR, PLS and PC-ANN

By  

Current Pharmaceutical Design, Vol. 19, Iss. 12, 2013-01 ,pp. : 2237-2244

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 137-142

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies

By Ng Terence   Cheung Yin Ting   Ng Quan Sing   Ho Han Kiat   Chan Alexandre  

Expert Opinion on Drug Safety, Vol. 13, Iss. 1, 2014-01 ,pp. : 83-92

Informa Healthcare

Access to resources Recommend Favorite